Blood Borne Infections Flashcards

1
Q

How do you calculate the risk of BBI transmission

A

Risk of BBI transmission = Risk that source is positive x risk per exposure.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

If a source is positive what is the chance of a needle stick injury causing an infection for Hep B, C and HIV?

A

If source positive
Hep B – 1 in 3
Hep C – 1 in 30
HIV – 1 in 300

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

How should a needle-stick injury be managed at the time of injury>

A

Immediate action
Encourage bleeding and wash
Risk assessment by Occupational health
Assess risk of source being positive – risk factors, known, viral load, HBV vaccine?
Nature of exposure – hollow vs solid needles, gloves, skin puncture etc.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

What post exposure prophylaxis should be offered to those who have a needle-stick injury where a patient was positive for a BBI?

A

Post exposure prophylaxis
• HIV – Triple anti-retroviral drugs for 28 days starting within 72 hours
• Hepatitis B – may need booster immunisation or immunoglobulins (if incompletely vaccinated or patient is HBsAg positive)
• Hepatitis C – no prophylaxis available

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

Who should be tested after a needlestick injury and what precautions should be taken by the recipient in the mean time?

A

Source patient – consent for HIV, HBsAg and HCV
Recipient – original blood sample stored – test at 4, 6, 12 and 24 weeks
Whilst waiting – safe sex, good infection control and avoid blood donations

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

What is HIV?

A

Virus that replicates and kills CD4 lymphocytes causing damage to the immune system over time if not controlled.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

How is HIV transmitted?

A

Sexual
Blood and bodily fluids – IVDU, needlestick and transplant/transfusion
Vertical – during birth or breast feeding (rare due to HAART – both maternal and neonatal)
Increased risk of transmission if: high viral load, STI causing anogenital inflammation or breaks in skin or mucosa

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

Describe the presentation of seroconversion illness of HIV

A

Seroconversion = change from seronegative to seropositive i.e. production of antibodies

Fever and rash – very common 
Malaise
Arthralgia and muscle aches
Sore Throat 
Lymphadenopathy
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

How does symptomatic HIV present?

A

Weight loss
High temperature
Diarrhoea
Frequent opportunistic infections e.g. herpes zoster or candidiasis

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

What is AIDS?

A

Aids is defined as a CD4 count of less than 200 and or opportunistic infections

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

How should suspected HIV be investigated?

A

Combo assay (ELISA) detecting HIV antibodies and the p24 antigen
Confirmatory tests in lab if positive – immunoblot
RNA detection in the blood for viral load
Contact tracing very important

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

What are the AIDS defining conditions

A
TB
Pneumocystis
Cerebral toxoplasmosis
Primary cerebral lymphoma 
Cryptococcal meningitis
Progressive multifocal leucoencephalopathy 
Kaposi’s sarcoma*
Persistent cryptosporidiosis
Non-Hodgkin’s lymphoma*
Cervical cancer*
Cytomegalovirus retinitis 
  • = AIDS defining cancers
    Wasting syndrome = loss of 10% body weight with fever over 30 days and chronic diarrhoea
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

How is HIV managed and what drugs does this involve?

A

HAART – highly active antiretroviral therapy – not a cure but viral load is undetectable
Excellent prognosis and risk of onward transmission is very small
HAART involves a number of classes of drugs:
• Nucleoside reverse transcriptase (NRTIs)
• Protease inhibitors (PIs)
• Non-nucleoside reverse transcriptase inhibitors (NRTIs)
• Integrase strand transfer inhibitors (InSTIs)
These are usually combined into one tablet taken daily. Compliance is very important and non-adherence can lead to resistance mutations.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

What is hepatitis C?

A

RNA virus causing Hepatitis. No vaccine but treatable

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

Describe how Hep C presents?

A
Usually asymptomatic 
Jaundice
Fatigue
Nausea
Fever
Muscle aches 

Incubation period of 6 weeks
20% clear the infection 80% progress to chronic infection – cirrhosis and hepatocellular carcinoma (1-5%)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

How is Hep C transmitted?

A
IVDU
Needlestick
Transfusion and haemodialysis 
Vertical (5%) mode of delivery and breast feeding no impact 
Sexual transmission – very low
17
Q

How should suspected Hep C be investigated?

A

Anti-HCV antibodies used for initial screening showing current or past infection

Positive 4-10 weeks after exposure (but offers incomplete protection allowing reinfection)

HCV RNA if Anti-HCV positive – distinguish current from past infection

LFTs – AST:ALT <1:1

Should always test for Hep A, B, C, D and E in any suspected hepatitis infection as well as CMV and Epstein Barr virus.

18
Q

How should Hep C be managed?

A

No vaccine
Risk modification
Curable with anti-viral but reinfection possible
Consider HepB vaccine for baby with infected mother due to clustering of risk factors

19
Q

What is Hep B?

A

Double stranded DNA virus causing chronic infection without a cure. Vaccine available

20
Q

Describe the clinical features of Hep B?

A
Fever
Urticaria 
Malaise
Anorexia
Nausea
Arthralgia
Jaundice
Hepatosplenomegaly
21
Q

How is Hep B transmitted?

A
Needlestick
IVDU
Transfusion (unscreened) 
Tattoos 
Renal dialysis in high-risk endemic countries 
Sexual 
Vertical
22
Q

How does Hep B progress?

A

Childhood infection – 10% spontaneously clear the virus
90% develop chronic infection leading to non-replicative cancer or chronic hepatitis. 40% develop cirrhosis

Adult infection – 99% develop acute hepatitis whilst less than 1% develop severe hepatic failure. 95% of those with acute infection will clear it. 5% develop chronic infection leading to non-replicative cancer or chronic hepatitis. 20% of those with chronic hepatitis will develop cirrhosis.

Acute infection = less than 6 months
Chronic infection = more than 6 months

23
Q

How should Hep B be investigated?

A

LFTs – very high in acute infection marginally high in carrier
Blood tests for serology
Surface antigen and antibody
Core antigen and antibody
Hep B e antigen (doesn’t last as long indicates acute vs chronic)

Surface antigen = current active infection IgM if acute IgG if chronic
Surface antibody = immune to Hep B infection or vaccinated
Core antibody = previous exposure to hepatitis B

Should always test for Hep A, B, C, D and E in any suspected hepatitis infection as well as CMV and Epstein Barr virus.

24
Q

What steps can be taken to reduce the risk of Hep B infection transmission?

A

Hep B positive cannot donate blood/organs/semen
Do not share needles
Condom use
Do not share razors or toothbrushes

25
Q

How should Hep B be managed?

A

No treatment other than vaccination

Sexual contacts tracing
Vaccination
HBIG if recent (within 7 days)
Use condoms/dental dams until immune